ID: ALA244434

Max Phase: Preclinical

Molecular Formula: C21H22BrClN6O6

Molecular Weight: 569.80

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)C[C@H](NC(=O)CNC(=O)c1cncc(NC2=NCC(O)CN2)c1)c1cc(Cl)cc(Br)c1O

Standard InChI:  InChI=1S/C21H22BrClN6O6/c22-15-3-11(23)2-14(19(15)34)16(4-18(32)33)29-17(31)9-25-20(35)10-1-12(6-24-5-10)28-21-26-7-13(30)8-27-21/h1-3,5-6,13,16,30,34H,4,7-9H2,(H,25,35)(H,29,31)(H,32,33)(H2,26,27,28)/t16-/m0/s1

Standard InChI Key:  IJCLIKANGQOCLK-INIZCTEOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 569.80

Molecular Weight (Monoisotopic): 568.0473

AlogP: 1.00

#Rotatable Bonds: 8

Polar Surface Area: 185.27

Molecular Species: ACID

HBA: 9

HBD: 7

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 3.12

CX Basic pKa: 8.16

CX LogP: -1.68

CX LogD: -2.12

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.24

Np Likeness Score: -0.60

References

1. Nagarajan SR, Devadas B, Malecha JW, Lu HF, Ruminski PG, Rico JG, Rogers TE, Marrufo LD, Collins JT, Kleine HP, Lantz MK, Zhu J, Green NF, Russell MA, Landis BH, Miller LM, Meyer DM, Duffin TD, Engleman VW, Finn MB, Freeman SK, Griggs DW, Williams ML, Nickols MA, Pegg JA, Shannon KE, Steininger C, Westlin MM, Nickols GA, Keene JL..  (2007)  R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.,  15  (11): [PMID:17399986] [10.1016/j.bmc.2007.03.034]

2. Sheldrake HM, Patterson LH..  (2014)  Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.,  57  (15): [PMID:24568695] [10.1021/jm5000547]

Source

Source(1):

• Scientific Literature